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Abstract
Background: Since the late 1980s, genetic discrimination has remained one of the major concerns associated with
genetic research and clinical genetics. Europe has adopted a plethora of laws and policies, both at the regional
and national levels, to prevent insurers from having access to genetic information for underwriting. Legislators
from the United States and the United Kingdom have also felt compelled to adopt protective measures specifically
addressing genetics and insurance. But does the available evidence really confirm the popular apprehension about
genetic discrimination and the subsequent genetic exceptionalism?
Methods: This paper presents the results of a systematic, critical review of over 20 years of genetic discrimination
studies in the context of life insurance.
Results: The available data clearly document the existence of individual cases of genetic discrimination. The
significance of this initial finding is, however, greatly diminished by four observations. First, the methodology used
in most of the studies is not sufficiently robust to clearly establish either the prevalence or the impact of
discriminatory practices. Second, the current body of evidence was mostly developed around a small number of
‘classic’ genetic conditions. Third, the heterogeneity and small scope of most of the studies prevents formal
statistical analysis of the aggregate results. Fourth, the small number of reported genetic discrimination cases in
some studies could indicate that these incidents took place due to occasional errors, rather than the voluntary or
planned choice, of the insurers.
Conclusion: Important methodological limitations and inconsistencies among the studies considered make it
extremely difficult, at the moment, to justify policy action taken on the basis of evidence alone. Nonetheless, other
empirical and theoretical factors have emerged (for example, the prevalence and impact of the fear of genetic
discrimination among patients and research participants, the (un)importance of genetic information for the
commercial viability of the private life insurance industry, and the need to develop more equitable schemes of
access to life insurance) that should be considered along with the available evidence of genetic discrimination for
a more holistic view of the debate.
Keywords: Evidence, genetic discrimination, genetic exceptionalism, GINA, life insurance, personalized medicine,
stigmatization, systematic review
Background
The prototypical issue used when discussing the ethical,
legal and social issues associated with scientific progress in
genetics has been genetic discrimination (GD). Lawyers
and ethicists have been quick to point out the risk that
uninhibited genetic progress would entice governments
and institutions to treat people differently on the basis of
their genetic constitution [1]. GD has been defined in
many ways, a mark of the influence of divergent sociocul-
tural and scholarly backgrounds. Insurers write of ‘rational
(actuarial)-irrational discrimination’ [2], lawyers write of
‘legal-illegal (illicit) discrimination’ [3], whereas patients
generally adopt a much broader definition encompassing
all differential, negative treatments of an individual based
on his or her genetic makeup [4]. However defined, wide-
spread GD could potentially result in practices that
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exclude segments of the population from access to basic
social necessities such as healthcare, insurance, housing,
reproductive freedom and employment. Mass media has
joined the debate, ensuring that the issue of GD is not
confined to isolated academic discourse [5].
Among the fields of potential discrimination, one of the
most commonly-debated topics has been the use of
genetic information by the insurance industry to select
applicants and determine insurance premiums. The dual
nature of personal insurance, which is partly considered as
both a public and private good in most jurisdictions, and
the relatively limited amount of public trust in the prac-
tices of the private insurance sector might explain some of
this attention. Policymakers themselves have entered the
arena of debate following substantial pressure from their
constituents. In continental Europe, the legislative
response has been swift and strong. GD is prohibited by
the Convention on Biomedicine (1997), the Charter of
Fundamental Rights of the European Union (2000), and
the national legislation of many individual countries [6]. In
the United States, the much-discussed Genetic Information
Nondiscrimination Act of 2008 (GINA) (2008) offers pro-
tection mainly in the domains of health insurance and
employment [7]. In the United Kingdom, the Association
of British Insurers and the British government have agreed
on a Concordat and Moratorium on Genetics and Insur-
ance that significantly restricts the capacity of British
insurers to request genetic information from insurance
applicants [8]. Australian (2008 amendment to the
Disability Discrimination Act), Canadian and East Asian
policymakers have also been active in this area, although
less so than their European counterparts [6,9].
This paper focuses on GD in the field of life insurance.
Life insurance facilitates the economic security of the
policy holder. It is often described as a quasi-essential
social good, a gateway good necessary to have access to
important social and economic activities that provide
considerable peace of mind to the policyholder [10].
Access to life insurance is far from universal and it must
generally be purchased through a contractual agreement
with a private insurance company. The majority of life
insurance applicants are accepted at a standard rate set
by insurance companies. Nevertheless, for the small
group of individuals excluded from the common pool,
the consequences can be dire [11].
Is the substantial attention given to the question of GD
in academic literature, popular media and policymaking
circles justified by the empirical evidence currently avail-
able? In other words, are the observed concerns and
responses based on documented cases of discrimination,
anecdotes or other less visible factors? This question
prompted us to undertake a study, which to our knowl-
edge is the first attempt to systematically review all avail-
able empirical evidence of GD using the life insurance
sector as a subject of analysis. This study analyzes actual
cases of discrimination, the evidentiary limitations, and the
possibility of drawing overarching conclusions from the
available evidence.
Methods
To assess the state of the evidence, we looked for all
studies published in the scientific literature documenting
the occurrence of GD in the context of life insurance.
Selection of publications
We developed and applied the following inclusion criteria
to identify and select eligible studies: published in English;
focused on the collection or capture of information on the
occurrence of GD in life insurance whether direct
(through patients’ or participants’ self-report, such as
interviews or surveys) or indirect (through professionals
such as doctors, genetic counselors and insurers); focused
on a primary or follow-up study (multiple publications on
the same study were grouped together and treated as a
single study). Narrative and systematic reviews were
included only if they also presented additional empirical
data on the occurrence of GD in the context of life insur-
ance (that is, other than the data contained in the studies
reviewed therein).
Eligible studies were excluded if: they did not focus in
whole or part on the occurrence of GD in the context of
life insurance; they offered insufficient evidence; or they
contained serious methodological flaws. Editorial letters
with no primary data, comments, opinions, abstracts and
unpublished studies were excluded. Studies capturing the
fear of GD rather than actual experiences were also
excluded.
Literature search
Searches were conducted from March until May 2012
on PubMed, Google Scholar, Social Science Research
Network and Hein Online, using the Boolean operators
‘OR’ and ‘AND’ with various permutations of the follow-
ing keywords: ‘genetic discrimination’, ‘study’, ‘life insur-
ance’, ‘survey’, ‘data’, ‘empirical evidence’ and ‘genetic
test’.
First, we conducted keyword searches that produced a
list including 534 search results. Using the terms ‘genetic
discrimination’ and ‘life insurance’ combined (‘AND’), we
obtained a list of 29 publications from the database
PubMed. We executed a search on Google Scholar includ-
ing all the following keywords combined (‘AND’): ‘genetic
discrimination’, ‘study’, ‘life insurance’, ‘survey’, ‘data’ and
‘empirical evidence’. This produced 155 search results.
Our search on Social Science Research Network using the
terms ‘genetic discrimination’ yielded 100 results. Our last
search was conducted on Hein Online using the following
combination of terms ‘(“genetic discrimination” AND “life
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insurance”) AND “genetic test” OR “data” OR “empirical
evidence” OR “survey"’, and generated 250 results.
Second, applying our selection criteria, we reviewed
the titles and available abstracts of each of the 534
search results identified through our keyword searches,
and retained 29 publications.
Third, we performed a systematic hand search in the
references list and bibliography of each of the 29 articles
to identify additional relevant publications and assess
cross-referencing. This led to 16 more eligible studies.
Hence, we uncovered a total of 45 eligible studies rele-
vant to GD in the context of life insurance.
Thereafter, eligible studies were each independently
assessed for relevance by two researchers (YJ, INF). Apply-
ing the selection criteria above, we retained studies docu-
menting experiences of discrimination through both direct
and indirect evidence on the occurrence of GD. Based on
these criteria, 12 studies were excluded. This final list was
also compared with references and resources provided by
a recent review dealing with GD in numerous contexts
including life insurance [9]. The 33 studies retained repre-
sent a systematic overview of the empirical evidence of
GD in the field of life insurance. For an overview of the
search strategy, see Figure 1.
Data extraction
The vastly different nature of the available studies sug-
gested that formal statistical analysis and comparison of
discrimination cases would be inappropriate. Instead, we
analyzed the data through a social science comparative
approach that incorporates both quantitative descriptive
analysis and qualitative content analysis. Key elements of
the selected studies were coded independently according
to their relevance to pre-selected themes. We extracted
information on study scope (country and context), genetic
conditions (whether the study focused on a single or mul-
tiple conditions), definition of GD (how GD was construed
by the researchers), validation (whether a formal validation
process was disclosed by the authors), conclusions (how
results were qualified: whether evidence of GD was found,
whether policies or laws were required), and number of
citations (how often the publication was cited by peers).
Two trained researchers (YJ, INF) independently evaluated
the results and discrepancies were resolved by consensus.
Results obtained on individual themes were qualitatively
analyzed and, where appropriate, converted to statistical
data (values were rounded according to convention;




Together, the 33 studies represent two decades’ worth of
research published from 1991 to 2012 (see Table 1).
A small peak in the number of studies (eight studies)
can be identified between 2006 and 2007, which can be
linked to the charged political climate in the US and
renewed academic interest that prefaced the adoption of
GINA. These studies generally gathered evidence
through direct sources (that is, individuals commenting
on their own experience with insurance companies), but
some obtained their data through secondary sources
such as insurers, insurance associations, health profes-
sionals or patient groups.
The majority of studies reviewed (73%) aimed at pro-
viding evidence of GD in a variety of fields (for example,
employment, immigration, adoption and access to health-
care), including that of life insurance. A minority (27%)
focused exclusively on the context of life insurance (see
Table 1). The majority of the available evidence (58%)
comes from studies involving North American popula-
tion groups (see Figure 2 and Table 2).
Surprisingly, given the rather strong European policy
response mentioned above, only six studies (18%) provided
empirical data on the situation prevailing in continental
Europe, and five of these studies were very specific in nat-
ure, addressing the context of familial hypercholesterole-
mia and hypertrophic cardiomyopathy in the Netherlands,
hereditary breast and colorectal cancer in Norway, and
Huntington’s disease in Germany [24,38,40,44].
The substantial number of studies carried out in Canada
(seven studies), where no specific laws have been adopted
to limit the use of genetic information by life insurers, and
the absence of studies in a highly legislated European con-
text, could suggest that the number of GD studies carried
out in a given country, as well as the number of GD cases
reported, does not necessarily have a strong correlative
impact on policymaking. A notable exception to this trend
could be Australia, whose Disability Act was amended fol-
lowing the publication of major studies on GD and an
extensive report from the Australian Law Reform Com-
mission [45].
Genetic conditions investigated
The mitigated overall results are not easily interpretable
and the task is exacerbated by the serious methodological
challenges faced in some of these studies. One of the con-
straints concerns the range of genetic diseases investigated
in the literature. Reviewing the scope of the 33 studies, it
is apparent that they only uncovered evidence on a very
limited number of highly penetrant, familial, adult-onset,
relatively well-known genetic conditions.
The majority of the evidence is based on the following
five conditions: Huntington’s disease, hereditary breast and
ovarian cancer, hemochromatosis, familial hypercholestero-
lemia and hereditary colorectal cancer (see Figure 3). Of
the 33 studies reviewed, 19 (58%) specifically focus on one
of these five conditions (see Figure 4). Moreover, evidence
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on genetic discrimination in the context of Huntington’s
disease is provided in over 14 of the 33 studies, and on her-
editary breast and ovarian cancer in more than 10 (see
Figure 3).
The high number of studies focusing on a single condi-
tion (see Figure 4) makes it particularly difficult to gener-
alize from the results of a systematic comparison of the
literature to reach a broad, robust conclusion on GD
applicable to the whole research or clinical genetic
context. Moreover, research on GD in the fields of perso-
nalized medicine and/or pharmacogenomics, infectious
diseases and genome-wide association studies remains
absent in the literature, thereby resulting in a complete
lack of data on GD in the context of emerging ‘omics’
research. This is particularly concerning given that the
amount of genomic information in the typical individual’s
medical record is likely to increase tremendously in the
next few years as whole-genome sequencing costs are
STEP 1:  
Keyword searches in PubMed, Google Scholar, SSNR and Hein Online 
n= 534 
STEP 2: 
Identification of relevant publications through title 
and abstract analysis based on inclusion criteria 
n= 29 
STEP 3: 
Hand search of the reference lists  and bibliographies 




Full text review of each article 
12 articles excluded 
n=33 
Figure 1 Methodology for selecting eligible studies.
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Table 1 Revised studies.













[12] 1991 United Kingdom Cholesterol screening and life assurance. Familial hypercholesterolemia. Yes No 1
[13] 1992 Canada, United States Discrimination as a consequence of
genetic testing.






[14] 1992 United States A survey of state insurance
commissioners concerning genetic
testing and life insurance.
Spina bifida, Huntington’s disease, cystic
fibrosis, breast cancer, coronary artery
disease and sickle cell anemia.
Yes No 2
[15] 1993 United States A survey of medical directors of life
insurance companies concerning use of
genetic information.
Spina bifida, Huntington’s disease, cystic
fibrosis, breast cancer, coronary artery
disease, and sickle cell anemia.
Yes Yes 1
[16] 1994 United States Genetic discrimination and screening for
hemochromatosis.
Hemochromatosis. No Yes 2
[17] 1996 United States Individual, family, and societal






[18] 1996 United States Genetic discrimination: perspectives of
consumers.
Conditions were not enumerated but
101 different primary genetic disorders
were represented.
No No 1
[4] 1998 United Kingdom Genetic discrimination in life insurance:
empirical evidence from a cross
sectional survey of genetic support
groups in the United Kingdom.
Cystic fibrosis, Huntington’s disease,
Marfan syndrome, muscular dystrophy,
myotonic dystrophy, neurofibromatosis
and tuberous sclerosis.




[19] 1998 United States Health, life and disability insurance and
hereditary non-polyposis colorectal
cancer.
Non-polyposis colorectal cancer. No No 2
[20] 1998 to 1999 Canada, United States “Genetic discrimination": results of a
survey of genetics professionals, primary
care physicians, patients and public.
Conditions were not enumerated. No No 2
[21] 2000 Europe Insurance considerations for individuals
with a high risk of breast cancer in
Europe: some recommendations.
Various conditions, including breast and
ovarian cancer, Von Hippel-Lindau
syndrome and hereditary non-polyposis
colon cancer.
No No 2 Some of the
countries included
in the study had
adopted laws or
policies
[22] 2000 Norway Health, life and disability insurance and
hereditary risk for breast or colorectal
cancer.























Table 1 Revised studies. (Continued)
[23] 2001 Australia Genetic discrimination in Australia. Various genetic conditions, including
breast and ovarian cancer, inherited
bowel cancer (familial adenomatous
polyposis), inherited bowel cancer
(hereditary non-polyposis colorectal
cancer), familial melanoma, rare cancer
syndrome, familial early-onset Alzheimer







disease), prion disease (Creutzfeldt-
Jakob disease), connective tissue
disorder (Marfan syndrome) and
myotonic dystrophy.
No No 1
[24] 2002 Netherlands Getting insurance after genetic
screening on familial
hypercholesterolemia; the need to
educate both insurers and the public to
increase adherence to national
guidelines in the Netherlands.
Familial hypercholesterolemia. Yes No 1 The Act on Medical
Examinations (1998)
[25] 2003 United States Life insurance and breast cancer risk
assessment: adverse selection, genetic
testing decisions, and discrimination.
Breast cancer. Yes No 3
[26] 2003 United States Insurance, employment, and
psychosocial consequences of a
diagnosis of hereditary
hemochromatosis in subjects without
end organ damage.
Hemochromatosis. No Yes 1
[27] 2004 United States Perceptions of genetic discrimination
among at-risk relatives of colorectal
cancer patients.
Colorectal cancer. No No 2
[28] 2004 United Kingdom Effect of statin treatment for familial
hypercholesterolaemia on life assurance:
results of consecutive surveys in 1990
and 2002.






[29] 2004 United Kingdom Psychosocial impact of breast/ovarian
(BRCA1/2) cancer-predictive genetic
testing in a UK multi-centre clinical
cohort.





















Table 1 Revised studies. (Continued)
[30] 2007 United Kingdom Predictive genetic testing for BRCA1/2 in
a UK clinical cohort: three-year follow-
up.





up study to [29]
[31] 2007 Canada, United States Genetic screening for iron overload: no
evidence of discrimination at 1 year.
Hemochromatosis. No Yes 2
[32-34] 2007 to 2009 Australia (1) Investigating genetic discrimination
in Australia: perceptions and experiences
of clinical genetics service clients
regarding coercion to test, insurance
and employment.
(2) Investigating genetic discrimination
in Australia: a large-scale survey of
clinical genetics clients.
(3) Verification of consumers’
experiences and perceptions of genetic
discrimination and its impact on
utilization of genetic testing.
Hereditary hemochromatosis; inherited
predisposition to blood clots (hereditary
thrombophilia); hereditary breast and
ovarian cancers; hereditary bowel
cancer (familial adenomatous polyposis
and hereditary non-polyposis colon
cancer; familial melanoma; rare
syndromes such as multiple endocrine
neoplasia, Von Hippel-Lindau syndrome;
neurodegenerative conditions (spino-
cerebellar ataxia; Huntington’s disease;
early-onset Alzheimer disease; motor




emphysema (for example, a-1
antitrypsin deficiency); adult polycystic
kidney disease and ‘other’.
No Yes 1 All three
publications relate
to the same study
[35] 2007 Australia The use of legal remedies in Australia
for pursuing allegations of genetic
discrimination: findings of an empirical
study.
No particular genetic condition was
sought after but case result pertained
to sickle cell.
No Yes 3
[3] 2007 Australia Investigating genetic discrimination in
the Australian life insurance sector: use
of genetic test results in underwriting
1999-2003.
No particular genetic condition was
sought after but results concerned:
hereditary hemochromatosis,
Huntington’s disease, breast and
ovarian cancer, cerebral autosomal
dominant arteriopathy with subcortical
infarcts and leukoencephalopathy,
colorectal cancer, hereditary non-
polyposis colorectal cancer, familial
adenomatous polyposis, thrombophilia
factor V (Leiden) mutation, prothrombin
gene mutation, Charcot-Marie-Tooth
disease, Marfan syndrome, myotonic
dystrophy, multiple endocrine
neoplasia, polycystic kidney disease, and
spinocerebellar ataxia.
Yes No 2 Study related to
Otlowski et al, 2007
[32-34]
[36] 2008 Canada Engagement with genetic
discrimination: concerns and experiences
in the context of Huntington disease.


















Table 1 Revised studies. (Continued)
[37] 2009 Canada Perceptions of genetic discrimination
among people at risk for Huntington’s
disease: a cross sectional survey.
Huntington’s disease. No No 1
[38] 2009 Austria, Germany,
United States
“A slap in the face”. An exploratory study
of genetic discrimination in Germany.






[39] 2009 United States Survey of unaffected BRCA and
mismatch repair (MMR) mutation
positive individuals.
BRCA. No No 2
[40] 2010 Netherlands Obtaining insurance after DNA
diagnostics: a survey among
hypertrophic cardiomyopathy mutation
carriers.
Hypertrophic cardiomyopathy. No No 2 The Act on Medical
Examinations (1998)
[41] 2010 Australia, Canada,
United States
Perception, experience, and response to
genetic discrimination in Huntington
disease: the international RESPOND-HD
study.







Act of 2008 (GINA)
[42] 2010 United States Views of discrimination among
individuals confronting genetic disease.
Huntington’s Disease, breast cancer,
and Alpha-1 antitrypsin deficiency.
No No 2 US, Genetic
Information
Nondiscrimination
Act of 2008 (GINA)
[43] 2012 Canada Beyond the patient: the broader impact
of genetic discrimination among
individuals at risk of Huntington disease.
Huntington’s disease. No No 1
[44] 2012 Netherlands Improved access to life insurance after
genetic diagnosis of familial
hypercholesterolaemia: cross-sectional
postal questionnaire study.
Familial hypercholesterolemia. Yes No 2 The Act on Medical
Examinations (1998)
Follow-up to [24].


















reduced and personalized medicine becomes more com-
mon in clinical settings [46].
Definition of genetic discrimination
The authors of the 33 studies all struggled with the mean-
ing of GD (examples of GD definitions are provided in
Table 3). Several studies refrained from using the term
‘genetic discrimination’ in their questionnaire so as to
avoid biasing responses. However, the paradoxical conse-
quence of this methodological approach was over-report-
ing due to the tendency of participants to declare any
negative outcome they faced while applying for life
insurance as an instance of discrimination [47]. When spe-
cifically included in survey questionnaires or data analysis
strategies, the definition of GD varied widely (see Table 3),
greatly reducing the possibility of meaningful comparison.
Indeed, the challenge of defining GD led a study author to
conclude that ‘[t]he notion of finding wholly objective and
overt evidence, as opposed to subjective and implicit
accounts of discrimination may [n]ot be entirely realistic’
[42]. Studies choosing to adopt a broad definition, or no
definition at all, tended to report the highest incidence of
GD cases [36]. Studies using a legal definition of GD














Figure 2 Studies on genetic discrimination and life insurance by country.
Table 2 Distribution of results on the evidence of genetic discrimination.
























(1) GD exists and is a
concern
5 8 2 9 5 4 10 14
(2) GD exists but is rare
and exceptional
5 10 2 8 8 3 13 16
(3) There was no evidence
of GD
1 1 1 2 1 1 2 3
aOut of 33. GD: genetic discrimination.
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vary significantly across jurisdictions, these studies are dif-
ficult to compare or integrate with one another outside of
their national context.
To obtain more robust and comparable results, some
studies have used the criteria of ‘irrational discrimination’ -
discrimination that is not based on scientifically validated
and actuarially relevant genetic information - as a selection
criterion to assess the practice of insurers. However,
because negative decisions by life insurers against some of
the most genetically at-risk individuals who might have
pressing need to obtain life insurance (for example, an
asymptomatic patient having tested positive for a mono-
genic dominant serious condition) would not necessarily
constitute irrational GD, use of this criterion could argu-
ably be perceived as unethical. The partly subjective nature
of the underwriting process (illustrated by the high
variability between the guidelines and questionnaires used
by different insurance companies) and our limited knowl-
edge of the genomics of complex diseases further limit the
use of the rationality criterion to determine objectively the
prevalence of GD in insurance.
The context of Huntington’s disease can be used to illus-
trate the impact of definitional choices on the results of
GD studies. Because this disease is a relatively well-known
autosomal dominant genetic condition, obtaining a posi-
tive test result has serious implications for the future
health of an asymptomatic individual. This explains the life
insurers’ interest in being able to use test results or family
history information, regarding this particular disease, for
underwriting. This is in turn reflected in the results of GD
studies. Studies investigating GD in the context of










Huntington's Disease  Hereditary Breast and 
Ovarian Cancer 
Hemochromatosis Hypercholesterolemia Colorectal Cancer Genetic  
conditions
No. of  
Studies 
Figure 3 Most studied genetic conditions in genetic discrimination and life insurance studies.
Huntington's Disease (5) 
Hereditary Breast and Ovarian Cancer (4)
Hypercholesterolemia (4) 
Hemochromatosis (3) 
Colorectal cancer (2) 
Hypertrophic cardiomyopathy (1) 
Non specific studies, i.e. more than one 
condition (14) 
Figure 4 Proportion of studies that focused on a single disease.
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or no definition at all would likely identify a significant
number of GD cases (exclusion, higher premiums or con-
ditional acceptance). However, studies using a rationality
or legality criteria would generally report a much lower
number of discrimination incidents.
Evidence of genetic discrimination
Around half of the studies reviewed (48%) found that,
although GD had some empirical basis, its incidence was
rare and it was not a significant source of insurance
denials [4,14,16,17,19-22,27,31,39,40,42,44]. A second cate-
gory, comprising a considerable number of studies (42%),
concluded that the existence of GD in life insurance was
documented by the evidence they provided and that the
situation gave grounds for serious concern. Within this
category, Huntington’s disease came up often [36-38,43].
Early US studies in this category often advocated the adop-
tion of laws and policies to prohibit access to genetic
information by life insurers [17] or the development of a
more generous public insurance system that would pro-
vide a minimum amount of life insurance to all applicants
[16]. Finally, a minority of studies (9%) found no empirical
evidence to support the existence of GD in the life insur-
ance context.
It should be mentioned that some, but not all, of the
countries covered by these studies, have already adopted
laws prohibiting insurers’ access to genetic information
(for example, the Netherlands, Norway, and Germany)
(see Table 1). Authors of the 9% of studies finding no
empirical evidence of GD were often of the opinion that
the GD problem was more linked to media hype and fear
of discrimination than to GD itself. These studies conse-
quently pointed out the importance of educating the
public and reassuring the concerns of patients and
research participants about GD [22,40].
Among the 19 studies dealing with a single genetic con-
dition (see Table 2), a significant number of studies (47%)
concluded that there was sufficient evidence to raise ser-
ious concerns about GD. Half of these studies concerned
Huntington’s disease [36-38,43]. A second important
category (42%) found that, while GD existed, it was of rare
occurrence [19,31,39,40,44]. Finally, a minority of studies
(11%) concluded there was no evidence of GD [25,28].
To highlight the broad trends, it is possible to further
group the 33 reviewed studies into two categories: a
majority of studies (58%) that believes that GD in the
context of life insurance is a negligible issue that does
not warrant the substantial societal debate and policy
concern generated to date, while a substantial minority
(42%) concludes that GD exists and has impacted access
to life insurance negatively.
Validation and methodological limitations
Validating the study results (that is, avoiding biases and
concealments as well as ensuring that the data reflect
cases of ‘real’ rather than ‘perceived’ discrimination) was
another significant hurdle. For the purpose of our
research, validation was considered to be any additional
independent step(s) or method(s) taken by the researcher
to confirm the accuracy of reported discrimination events.
A majority of the reviewed studies (76%) could not be con-
sidered as validated (see Table 1 and 2); in this case it
seems more accurate to talk about studies assessing the
‘perceived’ level of GD rather than objective manifestations
of it. Testifying to the importance of the validation pro-
cess, Wertz found that, ‘[W]hen asked to give details of
their refusals, almost all [participants] described situations
that are characteristic of general insurance practice. They
were apparently objecting to what they perceived as unfair
insurance practices in general, rather than practices speci-
fic to genetics.’ [20].
Studies of patients were not the only ones in which
investigators noted the importance of verifying findings.
Otlowski et al. observed that insurers surveyed on the
topic of GD were likely to under-report unfavorable
underwriting decisions [3].
To attempt to reduce the biases associated with non-
validated results, several verification techniques have
been used over the years. They include follow-up phone
calls or in-person interviews to elicit additional
Table 3 Examples of definitions of genetic discrimination.
Authors Reference Definition of genetic discrimination
Lapham et al.
1996
[18] Prejudicial action as perceived by the respondents that resulted from insurers’ or employers’ knowledge of an
individual’s genetic condition, carrier status, or presumed carrier status, based on observation, family history, genetic
testing, or other means of gathering genetic information.
Apse et al. 2004 [17] When people or organizations make unfair decisions about someone who is currently healthy based on genetic
information (results of genetic testing or family history information).
Taylor et al.,
2007
[34] Differential treatment of a person who has no manifest symptoms of a condition or disorder and which has occurred
allegedly on the basis of their genetic characteristics or makeup, either real or assumed.
Bombard et al.
2009




[41] The denial of rights, privileges, or opportunities or other adverse treatment based solely on genetic information,
including family history or genetic test results.
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information about reported cases of discrimination;
review of the participant’s medical file (to verify if an
unfavorable decision could be due to a pre-existing con-
dition); audit of the documentation or correspondence
relating to any discrimination complaint; corroboration
of discrimination reports by independent sources
(ombudsman or similar administrative instances); case
law; and so on. These validation techniques were used,
alone or in combination, with various degrees of rigor by
researchers and these choices significantly impacted the
results of the reviewed studies.
Other study limitations that impacted the results and
their compatibility with one another included the sample
size and type of people surveyed. Some studies would
include individuals already affected by a genetic disease
but asymptomatic [16], whereas others would include
healthy carriers [30]. Some would include asymptomatic
untested individuals with a family history of disease [37],
and some would include information on patients that
was obtained from indirect sources (family members,
genetic counselors or members of a disease support
group) [21]. The lack of large-scale studies of well-char-
acterized individuals also made it difficult to extrapolate
from the results to objectively estimate the prevalence of
GD in the life insurance sector.
Treloar and colleagues have written that, ‘conceptualiz-
ing, investigating and verifying individual’s experience of
genetic discrimination constitute a challenging endeavour’
[47]. Discrimination surely can take many subtle forms.
For example, rather than charging a higher premium or
excluding an applicant, an insurance company could
decide to process an application more slowly or ignore
phone calls and emails in the hope of discouraging pursuit
of the application process. In this case, the applicant might
not even be aware that she or he has been discriminated
against.
Given these serious challenges, it should come as no
surprise that the five most influential studies on GD within
academia, as measured by Web of Science and Google
Scholar citation rates (see Table 4), all suffer from impor-
tant limitations. For example, the most cited article on GD
in life insurance, a precursor 1992 pilot study by Billings et
al., used a broad definition of GD and reported 29
responses describing 41 separate incidents of possible dis-
crimination (32 in the field of insurance) [13]. The study
undertook an extensive advertising campaign (1,119 letters
mailed to genetic professionals, an advertisement in the
American Journal of Human Genetics, and similar adver-
tisements published in several patient organization news-
letters) to elicit this relatively small number of potential
discrimination cases from an under-defined population
that included symptomatic respondents. The authors of
the study acknowledged the limitations of their work stat-
ing that it is not meant to demonstrate the prevalence or
the full range of discriminatory practices. Nevertheless,
their conclusion that unfair and discriminatory use of
genetic data existed and that new laws and sanctions
should be considered does not seem to accord with the
limited data and exploratory methodology provided in the
study. Learning from early experiences and challenges in
this field, more recent studies tend to draw more cautious
or qualified conclusions and to recognize their own sub-
stantial methodological limitations [32].
Conclusions
This systematic review offers evidence that the literature
recognizes the existence of incidents of GD in North
America, Australia and the UK. We note four key obser-
vations. First, the methodology used in most of the stu-
dies is not sufficiently robust to clearly establish either
the prevalence or impact of discriminatory practices in
these regions. Second, the current body of evidence was
mostly developed around a very small number of ‘classic’
genetic conditions. Third, the heterogeneity and small
scope of most of the studies prevent formal statistical
analysis of the aggregate results. Fourth, the small num-
ber of reported cases of GD in some studies could indi-
cate that these incidents of GD took place due to error
(s), rather than voluntary or planned choice, of the
insurers.
These observations should not be interpreted as dis-
missing the importance of the significant work that has
been accomplished by researchers in this field over the
past 20 years. Our review has allowed us to confirm the
existence of GD, to identify large areas of evidentiary
gaps (for example, discrimination in the context of
‘omics’ studies) and methodological challenges (defining
GD, verification of reported incidents of GD), and to
identify promising methodologies to build upon for
future studies such as the one used for the Australian
Genetic Discrimination Project. In this project, a rich
body of evidence was gathered from a variety of sources
with special attention given to validation and methodo-
logical concerns [3,32,33,47]. This information can be
used by the international research community to con-
tinue monitoring and documenting experiences of GD
and its psychosocial and economic impact on individuals
with improved, more streamlined research strategies.
To return to our original question, can the intense
debate around GD in the life insurance context that has
taken place this past quarter-century be justified on the
basis of the available evidence? We must answer in the
negative. With the notable exception of studies on Hun-
tington’s disease, none of the studies reviewed here (or
their combination) brings irrefutable evidence of a sys-
temic problem of GD that would yield a highly negative
societal impact. From an ethical and policy standpoint,
looking at the evidence alone suggests that targeted
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Table 4 Most cited studies on genetic discrimination in life insurance.
Ranking Date Authors Title Reference Number of citations
1. 1992 PR Billings, MA Kohn, M de Cuevas, J Beckwith, JS Alper and MR
Natowicz
Discrimination as a consequence of genetic testing [13] Web of Science: 287
Google Scholar: 436
2. 1996 EV Lapham, C Kozma and JO Weiss Genetic discrimination: perspectives of consumers [18] Web of Science: 181
Google Scholar: 255
3. 1996 LN Geller, JS Alper, PR Billings, CI Barash, J Beckwith and MR Natowicz Individual, family, and societal dimensions of genetic discrimination: a
case study analysis
[17] Web of Science: N/A
Google Scholar: 127
4. 2004 M Watson, C Foster, R Eeles, D Ashley, R Davidson, J Mackay, PJ
Morrison, P Hopwood, DGR Evans and Psychosocial Study
Collaborators
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive
genetic testing in a UK multi-centre clinical cohort
[29] Web of Science: 60
Google Scholar: 92
5. 1998 L Low, S King and T Wilkie Genetic discrimination in life insurance: empirical evidence from a cross
sectional survey of genetic support groups in the United Kingdom



















policies (in the case of Huntington’s disease) and careful
monitoring of the situation as it evolves is likely the most
adequate course of action.
Nonetheless, other empirical and theoretical factors have
emerged that should be considered along with this empiri-
cal data. They include the prevalence and impact of the
fear of GD in patients and research participants, the
importance (or not) of genetic information for the com-
mercial viability of the private life insurance industry, and
the need to develop more equitable schemes of access to
life insurance. These factors, along with sociocultural and
historical elements linked to particular societies (such as
early experience with eugenics), would likely offer a better
explanation as to why the GD debate became so polarized
in popular and academic media. Finally, we wish to high-
light that it remains to be determined whether the current
GD dilemma is a sign of a broader discomfort with actuar-
ial practices, public policies and access to life insurance at
a time when many increasingly view this type of contrac-
tual protection as a good of important psychosocial value
that is necessary to obtain other important social and
commercial goods in post-industrial countries.
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